Slide 1: Investor Presentation
For personal use only Investor Presentation — 17 May 2023 (ASX: AUA) Approved for release by the Board of Audeara Limited.
Slide 2: Disclaimer | Important information
Disclaimer | Important information For personal use only 17 May 2023 This presentation has been prepared by Audeara Limited ACN 604 368 443 (Company) for the sole purpose of providing the Recipient with general information only. This presentation does not purport to be complete, nor does it contain
Slide 3: Business overview
Business overview For personal use only Audeara AUA Technology Headphones and accessories: Audeara ▸ White label products ▸ Audiology clinics Proprietary Technology ▸ Technology licensing ▹ Global chains ▸ Engineering services ▸ Australian retail channel Hardware | Firmware | Software Customer and h
Slide 4: Market updates | May 2023
Market updates | 17 May 2023 For personal use only ▸ Quarterly revenue up 104% vs Q3 FY22 ▸ Q3 FY23 cash receipts $1.01m, up 168% from the pcp ▸ YTD FY23 cash receipts $2.46m, up 85% from the pcp ▸ YTD FY23 net cash outflows $2.28m reduced 23% from the pcp ▸ $3.25 million in cash or equivalents at 3
Slide 5: Audeara: Hardware and software solutions for the hearing industry
For personal use only Audeara Hardware and software solutions for the hearing industry
Slide 6: The Audeara difference / Who is Audeara for?
The Audeara difference Who is Audeara for? For personal use only People with a hearing loss, Current hearing aid or cochlear Audeara headphones use who aren’t ready for hearing aids implant wearers a health-check algorithm^ to tailor sound to a unique hearing profile. Sound is clearer, not louder by
Slide 7: Clients | Audiology clinics
Clients | Audiology clinics For personal use only The problem for audiology clinics The value of Audeara to audiology clinics 45% Additional revenue stream of self declared hearing impaired adopt hearing As an Assistive Listening Device (ALD), Audeara provides clinics with aids* an additional revenu
Slide 8: Clients | Audiology clinics
Clients | Audiology clinics For personal use only Australia Audeara’s Number of locations that currently stock international opportunities Audeara (including sub-brands) (including sub-brands) ~9,241 locations# By 2030, nearly 645# in 25 countries 1 2,119.1 million EUR Consolidated 1.9 Revenue 1 ~2,
Slide 9: International distribution
International distribution expansion of clinics stocking Audeara For personal use only ASIAPAC Australia ▸ Currently stocked in over 1400 clinics. ▸ Primary revenue stream FY23 Taiwan ▸ Currently stocked in Clinico Inc. clinics – the largest audiology chain in Taiwan. ▸ Cooperative agreement signed
Slide 10: AUA Technology: Innovative listening solutions
For personal use only AUA Technology Innovative listening solutions
Slide 11: AUA Technology: Third party product development and technology licensing
AUA Technology For personal use only Third party product development and technology licensing Leverage Audeara Proprietary Technology for strategic opportunities outside of audiology industry. Audeara product pipeline Utilise Audeara Proprietary Technology to develop products in Audeara’s product pi
Slide 12: Global musical instrument brand
Global musical instrument brand For personal use only Product development agreement Contract manufacturing and Engineering fee for services licensing ▸ Design High volume consumer markets ▸ Sourcing with global reach. ▸ Product development Highly scalable products with well established sales channel
Slide 13: Clinico Inc.
Clinico Inc. For personal use only Cooperative agreement following strategic $2.8M investment Product development Exclusive distribution Developing a series of healthy In Taiwan and China, Audeara will Clinico Inc. is a Taiwanese company, hearing earbuds in conjunction with be exclusively distribute
Slide 14: Audeara product pipeline
Audeara product pipeline For personal use only Tailored listening software ▸ Audeara app (consumer mobile app) Headphones with tailored sound ▸ AudAssist (desktop app for clinics) A-01 Headphones A-02 Headphones A-03 Headphones Kids Research and development underway ▸ Musicians ▹ Hearing protection
Slide 15: Revenue
For personal use only Revenue Continual year on year growth + additional revenue streams
Slide 16: Sales by Half Year
Sales by Half Year For personal use only AUA Technology ▸ Engineering Services International Wholesale ▸ US - Independents, global chains ▸ EU - global chains ▸ Taiwan - Clinico Australian Wholesale ▸ Focus on increasing sales per clinic Australian Retail ▸ NDIS + E-Commerce Outlook
Slide 17: Outlook
For personal use only Outlook
Slide 18: Milestones and targets 2023 - 2024
Milestones and targets 2023 - 2024 For personal use only Previous quarter Current quarter FY24 targets January - March April - June Audeara ▸ WS Audiology Austria Audeara ▸ Australia: Wholesale and Retail Sales continued ▹ rollout to 21 clinics ▸ US Global Clinic Groups Year-on-Year Growth ▹ Expansi
Slide 19: Contact
For personal use only Contact INVESTOR ENQUIRIES Dr James Fielding Managing Director and Chief Executive Officer james.fielding@audeara.com
Slide 20: Company snapshot
Company snapshot For personal use only Enterprise value (A$) Top shareholders Share price $0.046 Name Shares Percentage Market cap $6.59M at 16 May 2023 Fortune Pioneer 28,000,000 19.5% Cash As at 31 March 2023 $3.247M Board of Directors 43,515,087 30.0% Debt As at 31 March 2023 $0 Other Top 20 31,3
Slide 21: Board Members
Board Members For personal use only Dr. James Fielding David Trimboli Pasquale ‘Paddy’ Rombola Dr. Elaine Saunders Bill Peng CEO and Managing Director Non-Executive Chairman Non-Executive Director Non-Executive Director Executive Director Dr Fielding completed dual bachelor’s Mr Trimboli helped laun